Novartis Ag (NVS) Liabilities from Discontinued Operations (2013 - 2023)
Novartis Ag recorded quarterly Liabilities from Discontinued Operations of 34000000.0 in Q2 2023, up 9.68% quarter-over-quarter from 31000000.0 in Q4 2019.
Novartis Ag's Liabilities from Discontinued Operations history runs 4 years deep, the most recent figure standing at 34000000.0 for Q2 2023.
- In Q2 2023, Liabilities from Discontinued Operations changed N/A year-over-year to 34000000.0; the TTM figure through Jun 2023 stood at 34000000.0 (changed N/A YoY), while the FY2019 annual figure was 31000000.0, down 39.22% from the prior year.
- Liabilities from Discontinued Operations came in at 34000000.0 for Q2 2023 at Novartis Ag, up from 31000000.0 in the prior quarter.
- In the past five years, Liabilities from Discontinued Operations ranged from a high of 50000000.0 in Q2 2019 to a low of 24000000.0 in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 34.00 Mn |
| Jun 30, 2023 | 34.00 Mn |
| Dec 31, 2019 | 31.00 Mn |
| Dec 31, 2019 | 31.00 Mn |
| Sep 30, 2019 | 24.00 Mn |
| Sep 30, 2019 | 24.00 Mn |
| Jun 30, 2019 | 50.00 Mn |
| Jun 30, 2019 | 50.00 Mn |
| Mar 31, 2019 | 41.00 Mn |
| Mar 31, 2019 | 41.00 Mn |
| Dec 31, 2018 | 51.00 Mn |
| Dec 31, 2018 | 51.00 Mn |
| Sep 30, 2018 | 76.00 Mn |
| Sep 30, 2018 | 76.00 Mn |
| Dec 31, 2013 | 50.00 |
| Dec 31, 2013 | 50.00 |